Cardiac technology company HeartBeam has received an automated cardiac detection patent for its HeartBeam AIMIGosystem.
The United States Patent and Trademark Office has granted the company a notice of allowance for a patent associated with the initial artificial intelligence (AI) capability in the HeartBeam AIMIGo system.
The HeartBeam AIMIGo system is a portable, personal and easy-to-use vector electrocardiogram (VECG) solution for heart attack detection.
It is designed to aid patients and their healthcare providers in evaluating cardiac symptoms.
Patients can place the system’s reusable, credit card-sized VECG recording device on their chest for 30 seconds to enable electrocardiogram (ECG) signal recording.
The system also uses advanced cloud-based software to enable healthcare providers to receive crucial real-time data from outside of medical facilities.
HeartBeam CEO and founder Dr Branislav Vajdic said: “We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG.
“We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and save lives.”
The recently approved patent outlines a system that combines recorded cardiac signals from the HeartBeam AIMIGo VECG device with a patient’s symptoms and cardiac risk factors. This resultant cardiac risk score offers easy-to-understand diagnostic information and provides the patient with actionable instructions.
The HeartBeam AIMIGo device’s objective is to automate the evaluation of patients with cardiac symptoms, replicating the decision-making process of physicians.